All In Biotech

Drug Trial Radar · NCT04023552

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease

Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 8,323 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,323

Actual

Start

Dec 12, 2019

Primary completion

Jul 16, 2026

Study completion Jul 16, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 17, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)

Conditions

  • Cardiovascular Disease and Lipoprotein(a)

Interventions

  • TQJ230Drug

    TQJ230 80 mg injected monthly administered subcutaneously

  • PlaceboDrug

    Placebo to match TQJ230 prefilled syringe to be injected subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first occurrence of clinical endpoint committee confirmed expanded major adverse cardiovascular events in patients with elevated Lp(a) ≥ 70 mg/dLTime frame: approximately 4 years
  2. Time to the first occurrence of clinical endpoint committee confirmed expanded major adverse cardiovascular events in a population of patients with elevated Lp(a) ≥ 90 mg/dL.Time frame: approximately 4 years

Locations

902 sites in 43 countries. Site status is shown where the registry gives one.

  • SEC Clinical Research LLC

    Andalusia, Alabama

  • Grandview Med Group Research LLC

    Birmingham, Alabama

  • Novartis Investigative Site

    Birmingham, Alabama

  • Heart Center Research Llc

    Huntsville, Alabama

  • Novartis Investigative Site

    Huntsville, Alabama

  • Mobile Heart Specialists

    Mobile, Alabama

  • Novartis Investigative Site

    Mobile, Alabama

  • Novartis Investigative Site

    Cottonwood, Arizona

  • Mercy Gilbert Medical Center

    Gilbert, Arizona

  • Clinical Research Inst of Arizona

    Sun City West, Arizona

  • Novartis Investigative Site

    Sun City West, Arizona

  • Eclipse Clinical Research

    Tucson, Arizona

  • Novartis Investigative Site

    Tucson, Arizona

  • Cardiology and Medicine Clinic PA

    Little Rock, Arkansas

  • Novartis Investigative Site

    Little Rock, Arkansas

  • Cardiovascular Res Found

    Beverly Hills, California

  • National Heart Institute

    Beverly Hills, California

  • Novartis Investigative Site

    Beverly Hills, California

  • Flourish Clinical Resrch Covin

    Covina, California

  • Novartis Investigative Site

    Covina, California

  • Diabetes Lipid Management Center

    Huntington Beach, California

  • Novartis Investigative Site

    Huntington Beach, California

  • University of Calif Irvine Med Cntr

    Irvine, California

  • Novartis Investigative Site

    La Jolla, California

  • Memorial Care Health System

    Long Beach, California

  • Novartis Investigative Site

    Long Beach, California

  • Keck Medical Center USC

    Los Angeles, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Northridge, California

  • Valley Clinical Trials

    Northridge, California

  • Novartis Investigative Site

    Orange, California

  • Stanford University Medical Center

    Palo Alto, California

  • University of California San Diego

    San Diego, California

  • UCSF

    San Francisco, California

  • Novartis Investigative Site

    San Francisco, California

  • Helping Hands Medical Associates INC

    Santa Ana, California

  • Novartis Investigative Site

    Santa Ana, California

  • Novartis Investigative Site

    Stanford, California

  • Manshadi Heart Institute

    Stockton, California

Showing 40 of 902 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.